Lenalidomide Stragen (Lenalidomide)

• Lenalidomide is used in hematologic oncology to target malignant plasma cells and dysplastic bone‑marrow clones.
• Multiple Myeloma: improves progression‑free and overall survival in patients with relapsed or refractory disease.
• Myelodysplastic Syndromes: reduces transfusion dependence and delays progression to acute leukemia.
• Myelodysplastic Syndrome with del(5q) deletion: corrects anemia and decreases need for red‑cell support.

• Lenalidomide binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex, altering substrate specificity and promoting degradation of transcription factors such as Ikaros and Aiolos. This leads to modulation of cytokine production, inhibition of angiogenesis, and induction of apoptosis in malignant cells, while enhancing natural killer and T‑cell mediated immune responses.

Lenalidomide may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Fatigue: persistent tiredness affecting daily activities.
• Neutropenia: reduced neutrophil count increasing infection risk.
• Thrombocytopenia: low platelet levels leading to easy bruising.
• Anemia: decreased red blood cells causing weakness.
• Diarrhea: loose stools that may require hydration.
• Rash: skin irritation or redness.

Serious or Rare Side Effects

• Venous thromboembolism: blood clots in deep veins or lungs.
• Severe neutropenia: profound infection susceptibility.
• Severe thrombocytopenia: risk of serious bleeding.
• Secondary primary malignancies: emergence of new cancers.
• Severe liver injury: marked elevation of hepatic enzymes.
• Hypersensitivity reactions: including anaphylaxis.

• Before initiating therapy, clinicians should evaluate specific safety considerations.
• Pregnancy Contraindication: Lenalidomide is teratogenic and must not be used during pregnancy.
• Thrombosis Risk: Assess patient history and consider prophylactic anticoagulation when appropriate.
• Blood Count Monitoring: Perform regular CBCs to detect cytopenias early.
• Renal Impairment: Adjust dosing in patients with reduced kidney function.
• Hepatic Impairment: Use caution in severe liver disease.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Lenalidomide can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase exposure.
• Strong CYP3A4 inducers (e.g., rifampin): may reduce efficacy.
• Anticoagulants (e.g., warfarin): heightened risk of bleeding.

Moderate Interactions (Monitor Closely)

• NSAIDs: additive risk of gastrointestinal bleeding.
• CYP3A4 substrates (e.g., midazolam): may require dose adjustment.